Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Targeted resequencing identifies PTCH1 as a major contributor to ocular developmental anomalies and extends the SOX2 regulatory network.

Chassaing N, Davis EE, McKnight KL, Niederriter AR, Causse A, David V, Desmaison A, Lamarre S, Vincent-Delorme C, Pasquier L, Coubes C, Lacombe D, Rossi M, Dufier JL, Dollfus H, Kaplan J, Katsanis N, Etchevers HC, Faguer S, Calvas P.

Genome Res. 2016 Apr;26(4):474-85. doi: 10.1101/gr.196048.115. Epub 2016 Feb 18.

2.

Molecular findings and clinical data in a cohort of 150 patients with anophthalmia/microphthalmia.

Chassaing N, Causse A, Vigouroux A, Delahaye A, Alessandri JL, Boespflug-Tanguy O, Boute-Benejean O, Dollfus H, Duban-Bedu B, Gilbert-Dussardier B, Giuliano F, Gonzales M, Holder-Espinasse M, Isidor B, Jacquemont ML, Lacombe D, Martin-Coignard D, Mathieu-Dramard M, Odent S, Picone O, Pinson L, Quelin C, Sigaudy S, Toutain A, Thauvin-Robinet C, Kaplan J, Calvas P.

Clin Genet. 2014 Oct;86(4):326-34. doi: 10.1111/cge.12275. Epub 2013 Oct 7.

PMID:
24033328
3.

Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.

Mazard T, Causse A, Simony J, Leconet W, Vezzio-Vie N, Torro A, Jarlier M, Evrard A, Del Rio M, Assenat E, Martineau P, Ychou M, Robert B, Gongora C.

Mol Cancer Ther. 2013 Oct;12(10):2121-34. doi: 10.1158/1535-7163.MCT-12-0966. Epub 2013 Aug 19.

4.

MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy.

Paillas S, Causse A, Marzi L, de Medina P, Poirot M, Denis V, Vezzio-Vie N, Espert L, Arzouk H, Coquelle A, Martineau P, Del Rio M, Pattingre S, Gongora C.

Autophagy. 2012 Jul 1;8(7):1098-112. doi: 10.4161/auto.20268. Epub 2012 May 31.

5.

Efficacy of ceftriaxone and doxycycline in the treatment of early syphilis.

Psomas KC, Brun M, Causse A, Atoui N, Reynes J, Le Moing V.

Med Mal Infect. 2012 Jan;42(1):15-9. doi: 10.1016/j.medmal.2011.10.003. Epub 2011 Nov 25.

PMID:
22119040
6.

New Topoisomerase I mutations are associated with resistance to camptothecin.

Gongora C, Vezzio-Vie N, Tuduri S, Denis V, Causse A, Auzanneau C, Collod-Beroud G, Coquelle A, Pasero P, Pourquier P, Martineau P, Del Rio M.

Mol Cancer. 2011 May 27;10:64. doi: 10.1186/1476-4598-10-64.

7.

Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.

Paillas S, Boissière F, Bibeau F, Denouel A, Mollevi C, Causse A, Denis V, Vezzio-Vié N, Marzi L, Cortijo C, Ait-Arsa I, Askari N, Pourquier P, Martineau P, Del Rio M, Gongora C.

Cancer Res. 2011 Feb 1;71(3):1041-9. doi: 10.1158/0008-5472.CAN-10-2726. Epub 2010 Dec 15.

8.

Novel B3GALTL mutation in Peters-plus Syndrome.

Dassie-Ajdid J, Causse A, Poidvin A, Granier M, Kaplan J, Burglen L, Doummar D, Teisseire P, Vigouroux A, Malecaze F, Calvas P, Chassaing N.

Clin Genet. 2009 Nov;76(5):490-2. doi: 10.1111/j.1399-0004.2009.01253.x. Epub 2009 Sep 30. No abstract available.

PMID:
19796186
9.

Involvement of ATM missense variants and mutations in a series of unselected breast cancer cases.

Rodriguez C, Vallès H, Causse A, Johannsdottir V, Eliaou JF, Theillet C.

Genes Chromosomes Cancer. 2002 Feb;33(2):141-9.

PMID:
11793440
10.

At least five regions of imbalance on 6q in breast tumors, combining losses and gains.

Rodriguez C, Causse A, Ursule E, Theillet C.

Genes Chromosomes Cancer. 2000 Jan;27(1):76-84.

PMID:
10564589
11.

Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations.

Cuny M, Simony-Lafontaine J, Rouanet P, Grenier J, Valles H, Lavaill R, Louason G, Causse A, Lequeux N, Thierry C, et al.

Oncol Res. 1994;6(4-5):169-76.

PMID:
7841539
12.

Enzyme immunoassay for human chorionic gonadotropin using monoclonal antibodies elicited with a synthetic peptide.

Longhi B, Chichehian B, Causse A, Caraux J.

J Immunol Methods. 1986 Aug 21;92(1):89-95.

PMID:
3745924
13.

Human T-lymphocyte colonies: generation of colonies in different lymphocyte subpopulations.

Klein B, Caraux J, Thierry C, Gauci L, Causse A, Serrou B.

Immunology. 1981 May;43(1):39-45.

14.

Human T lymphocyte colonies. I. Surface markers and cytotoxic potential of colony cells.

Klein B, Caraux J, Causse A, Thierry C, Serrou B.

Biomedicine. 1981 Feb;34(1):34-9.

PMID:
6971656
15.

Comparative effects of acetazolamide and prussian blue on 137-Cs retention in the rat.

Ducousso R, Causse A, Pasquier C.

Health Phys. 1975 Jan;28(1):75-8. No abstract available.

PMID:
1110170
16.

Long-term treatment of cesium 137 contamination with colloidal and a comparison with insoluble prussian blue in rats.

Müller WH, Ducousso R, Causse A, Walter C.

Strahlentherapie. 1974 Mar;147(3):319-22. No abstract available.

PMID:
4844438
17.

[Bronchographies using tantalum aerosol. Toxicological study of the contrast medium].

Ducousso R, Causse A, Masse R, Kermarec J.

J Radiol Electrol Med Nucl. 1973 Nov;54(11):813-21. French. No abstract available.

PMID:
4208877

Supplemental Content

Loading ...
Support Center